Back in May, Cytiva completed its integration with Pall Life Sciences, a move that CEO Emmanuel Ligner now describes as a “winning recipe” which has improved the company’s supply chain and fostered industry collaboration.
Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells...
Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally
Pall Biotech signs an industry participation agreement with the New Jersey Innovation Institute to create two centres designed to develop and manufacture cell and gene therapies.
GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.
Pall Corporation has developed a control system for its single-use benchtop bioreactor and says it will continue to invest in-house for process control technologies.
Pall has licensed a ‘filterless filter’ technology which developers FloDesignSonic says bridges the gap between the up and downstream in continuous bioprocessing.
The acquisition of Pall Corporation by either Thermo Fisher or Danaher could spur further M&A in the life science tech industry, according to an analyst.
Uptake in single-use is “off the charts” but there is still a growing market for traditional stainless steel technology, says Pall following its acquisition of ATMI.
Buying ATMI will help Pall fill gaps in its up and downstream biomanufacturing tech offerings but the deal does not rule out other acquisitions says CEO, Larry Kingsley
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Pall Life Sciences has launched its Allegro 3D biocontainers, which have been designed to improve the performance of the company’s large-scale, single use manufacturing systems.
